Webinar: New Data on the Future of CNS Clinical Trials
In this special webinar event, Science 37 will present the results of a new study that will look at how future trends in clinical research will affect the CNS (central nervous system) space.
The event is taking place on Tuesday, March 1, 2022, at 11:00 am EST / 4:00 pm GMT / 5:00 pm CET. It will feature our in-house clinical experts in Neurology, Psychiatry, and Behavioral Science who will help explain the significance of the results and answer audience questions.
This notable presentation and discussion will explore the following topics:
- What types of CNS clinical trials sponsors and CROs have planned for the next 12 months vs. those executed in the past year (including Major Depressive Disorder, Schizophrenia, PTSD, Migraine, Parkinson’s, Alzheimer’s, Multiple Sclerosis, ADHD, and Seizures/Epilepsy.)
- Which decentralized components have been, and will be, most important in CNS clinical trials.
- What are the perceived benefits and challenges of using DCT approaches to execute CNS trials.
- How sponsors have been and will be, using wearables and sensors in CNS trials.
Speakers:
- Dr. David Kudrow, Medical Director, Neurology, Science 37
- Dr. Christopher Reist, Medical Director, Psychiatry and Behavioral Sciences, Science 37
- Drew Bustos, Chief Strategy and Marketing Officer, Science 37
- James Chase, Senior Director, Thought Leadership, Science 37